Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Neutrophils Display Novel Partners of Cytosolic Proliferating Cell Nuclear Antigen Involved in Interferon Response in COVID-19 Patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Karger Country of Publication: Switzerland NLM ID: 101469471 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1662-8128 (Electronic) Linking ISSN: 1662811X NLM ISO Abbreviation: J Innate Immun Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel, Switzerland : Karger, c2009-
    • Subject Terms:
    • Abstract:
      Introduction: Neutrophils are key players in the hyperinflammatory response during SARS-CoV-2 infection. The cytosolic proliferating cell nuclear antigen (PCNA) is a scaffolding protein highly dependent on the microenvironment status and known to interact with numerous proteins that regulate neutrophil functions. This study aimed to examine the cytosolic protein content and PCNA interactome in neutrophils from COVID-19 patients.
      Methods: Proteomic analyses were performed on neutrophil cytosols from healthy donors and patients with severe or critical COVID-19. In vitro approaches were used to explore the biological significance of the COVID-19-specific PCNA interactome.
      Results: Neutrophil cytosol analysis revealed a strong interferon (IFN) protein signature, with variations according to disease severity. Interactome analysis identified associations of PCNA with proteins involved in interferon signaling, cytoskeletal organization, and neutrophil extracellular trap (NET) formation, such as protein arginine deiminase type-4 (PADI4) and histone H3, particularly in critical patients. Functional studies of interferon signaling showed that T2AA, a PCNA scaffold inhibitor, downregulated IFN-related genes, including STAT1, MX1, IFIT1, and IFIT2 in neutrophils. Additionally, T2AA specifically inhibited the secretion of CXCL10, an IFN-dependent cytokine. PCNA was also found to interact with key effector proteins implicated in NET formation, such as histone H3, especially in critical COVID-19 cases.
      Conclusion: The analysis of the PCNA interactome has unveiled new protein partners that enhance the interferon pathway, thereby modulating immune responses and contributing to hyperinflammation in COVID-19. These findings provide valuable insights into interferon dysregulation in other immune-related conditions.
      Introduction: Neutrophils are key players in the hyperinflammatory response during SARS-CoV-2 infection. The cytosolic proliferating cell nuclear antigen (PCNA) is a scaffolding protein highly dependent on the microenvironment status and known to interact with numerous proteins that regulate neutrophil functions. This study aimed to examine the cytosolic protein content and PCNA interactome in neutrophils from COVID-19 patients.
      Methods: Proteomic analyses were performed on neutrophil cytosols from healthy donors and patients with severe or critical COVID-19. In vitro approaches were used to explore the biological significance of the COVID-19-specific PCNA interactome.
      Results: Neutrophil cytosol analysis revealed a strong interferon (IFN) protein signature, with variations according to disease severity. Interactome analysis identified associations of PCNA with proteins involved in interferon signaling, cytoskeletal organization, and neutrophil extracellular trap (NET) formation, such as protein arginine deiminase type-4 (PADI4) and histone H3, particularly in critical patients. Functional studies of interferon signaling showed that T2AA, a PCNA scaffold inhibitor, downregulated IFN-related genes, including STAT1, MX1, IFIT1, and IFIT2 in neutrophils. Additionally, T2AA specifically inhibited the secretion of CXCL10, an IFN-dependent cytokine. PCNA was also found to interact with key effector proteins implicated in NET formation, such as histone H3, especially in critical COVID-19 cases.
      Conclusion: The analysis of the PCNA interactome has unveiled new protein partners that enhance the interferon pathway, thereby modulating immune responses and contributing to hyperinflammation in COVID-19. These findings provide valuable insights into interferon dysregulation in other immune-related conditions.
      (© 2025 The Author(s). Published by S. Karger AG, Basel.)
    • References:
      Nucleic Acids Res. 2023 Jan 6;51(D1):D1539-D1548. (PMID: 36370099)
      Cytokine. 2023 Feb;162:156111. (PMID: 36529030)
      Nat Immunol. 2021 Jan;22(1):32-40. (PMID: 33277638)
      Nat Commun. 2018 Jul 27;9(1):2958. (PMID: 30054480)
      Cells. 2022 Nov 26;11(23):. (PMID: 36497044)
      Trends Immunol. 2019 Jul;40(7):648-664. (PMID: 31155315)
      J Exp Med. 2020 Dec 7;217(12):. (PMID: 32750141)
      Front Immunol. 2021 Jan 05;11:584116. (PMID: 33469455)
      PLoS One. 2022 Apr 14;17(4):e0264979. (PMID: 35421120)
      J Exp Med. 2019 Nov 4;216(11):2669-2687. (PMID: 31492810)
      J Matern Fetal Neonatal Med. 2007 Nov;20(11):777-92. (PMID: 17943641)
      Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7326-7337. (PMID: 32170015)
      J Leukoc Biol. 2024 Jan 19;115(2):201-204. (PMID: 38057160)
      Front Immunol. 2022 May 25;13:836754. (PMID: 35693822)
      J Exp Med. 2010 Nov 22;207(12):2631-45. (PMID: 20975039)
      Blood. 2020 Sep 3;136(10):1169-1179. (PMID: 32597954)
      Nat Commun. 2022 Nov 25;13(1):7254. (PMID: 36434007)
      J Biol Chem. 2014 Mar 7;289(10):7109-7120. (PMID: 24474685)
      J Cell Biol. 2017 Dec 4;216(12):4073-4090. (PMID: 29150539)
      Nat Commun. 2020 Oct 16;11(1):5243. (PMID: 33067472)
      J Autoimmun. 2019 Mar;98:122-131. (PMID: 30704942)
      J Exp Med. 2007 Oct 1;204(10):2423-37. (PMID: 17893202)
      Elife. 2017 Jun 02;6:. (PMID: 28574339)
      Eur J Immunol. 1997 Jan;27(1):111-5. (PMID: 9022006)
      Nat Immunol. 2022 Oct;23(10):1470-1483. (PMID: 36138183)
      Methods Mol Biol. 2023;2426:243-265. (PMID: 36308692)
      J Exp Med. 2020 Dec 7;217(12):. (PMID: 32926097)
      J Leukoc Biol. 2020 Jul;108(1):17-41. (PMID: 32534467)
      Cell Rep Med. 2022 Oct 18;3(10):100779. (PMID: 36208629)
      Science. 2020 Oct 23;370(6515):. (PMID: 32972995)
      J Innate Immun. 2022;14(5):393-417. (PMID: 35263752)
      Sci Rep. 2016 Oct 19;6:35561. (PMID: 27759041)
      J Immunol. 2009 Jun 1;182(11):7254-63. (PMID: 19454722)
      JCI Insight. 2021 Sep 22;6(18):. (PMID: 34403366)
      Blood. 2019 May 16;133(20):2178-2185. (PMID: 30898862)
      Eur Respir J. 2024 Mar 7;63(3):. (PMID: 38097207)
      Sci Rep. 2016 Jan 21;6:19674. (PMID: 26790609)
      Immunol Rev. 2023 Mar;314(1):427-441. (PMID: 36326284)
      Front Immunol. 2022 Feb 09;13:826515. (PMID: 35251008)
      J Biol Chem. 2012 Apr 20;287(17):14289-300. (PMID: 22383522)
      Lab Invest. 2009 Oct;89(10):1084-99. (PMID: 19636293)
      Eur J Immunol. 2019 Feb;49(2):221-227. (PMID: 30629284)
      Commun Biol. 2021 Mar 5;4(1):290. (PMID: 33674719)
      Eur J Immunol. 2007 Sep;37(9):2627-34. (PMID: 17668902)
      J Exp Med. 2020 Dec 7;217(12):. (PMID: 32926098)
      Sci Transl Med. 2022 Nov 16;14(671):eabo5795. (PMID: 36383686)
      Eur J Immunol. 2022 Mar;52(3):484-502. (PMID: 34870329)
      Br J Haematol. 2022 Oct;199(1):61-64. (PMID: 35818311)
      Science. 2004 Mar 5;303(5663):1532-5. (PMID: 15001782)
      Mol Med. 2021 Oct 18;27(1):129. (PMID: 34663207)
      Nat Immunol. 2014 Jul;15(7):602-11. (PMID: 24940954)
      Semin Immunol. 2016 Apr;28(2):137-45. (PMID: 27021499)
      Front Immunol. 2022 Jun 01;13:864387. (PMID: 35720378)
      Front Immunol. 2023 May 22;14:1145840. (PMID: 37283736)
      J Leukoc Biol. 2024 Sep 2;116(3):456-468. (PMID: 38452242)
      Inflammation. 2018 Mar;41(2):710-721. (PMID: 29322364)
      J Cell Biol. 2009 Jan 26;184(2):205-13. (PMID: 19153223)
      Inflamm Res. 2023 Jun;72(6):1175-1192. (PMID: 37212866)
      Cell Death Differ. 2021 Nov;28(11):3125-3139. (PMID: 34031543)
      Haematologica. 2021 Sep 01;106(9):2493-2498. (PMID: 33832219)
      Nat Rev Immunol. 2011 Jul 25;11(8):519-31. (PMID: 21785456)
      J Leukoc Biol. 2006 Jan;79(1):123-32. (PMID: 16244105)
      J Leukoc Biol. 2024 Jan 19;115(2):205-221. (PMID: 37824822)
      JCI Insight. 2024 Apr 8;9(7):. (PMID: 38470488)
      J Immunol. 1999 Apr 15;162(8):4928-37. (PMID: 10202039)
      Br J Pharmacol. 2023 Jun;180(11):1460-1481. (PMID: 36526272)
      Circulation. 2020 Nov 3;142(18):1787-1790. (PMID: 32946302)
      Immunol Rev. 2016 Sep;273(1):344-56. (PMID: 27558345)
      Cell Metab. 2021 May 4;33(5):1062-1064. (PMID: 33951466)
      J Innate Immun. 2023;15(1):850-864. (PMID: 37939687)
      Front Immunol. 2016 Apr 26;7:160. (PMID: 27199985)
      Cell. 2020 Sep 17;182(6):1419-1440.e23. (PMID: 32810438)
      Sci Rep. 2020 Nov 12;10(1):19630. (PMID: 33184506)
      Proc Natl Acad Sci U S A. 2022 Mar 15;119(11):. (PMID: 35217532)
      J Exp Med. 2010 Sep 27;207(10):2053-63. (PMID: 20837696)
      Science. 2020 Sep 4;369(6508):1210-1220. (PMID: 32788292)
      Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28336-28343. (PMID: 33082228)
      Nat Med. 2009 Nov;15(11):1318-21. (PMID: 19855397)
      Clin Exp Immunol. 2021 Feb;203(2):151-159. (PMID: 32990354)
      Bioinformatics. 2020 May 1;36(10):3148-3155. (PMID: 32096818)
      Am J Respir Crit Care Med. 2020 Sep 15;202(6):812-821. (PMID: 32584597)
      Wellcome Open Res. 2021 Feb 22;6:38. (PMID: 33997298)
      J Biol Chem. 2012 Sep 28;287(40):33812-25. (PMID: 22846997)
      J Exp Med. 2020 Jun 1;217(6):. (PMID: 32302401)
      Science. 2020 Aug 7;369(6504):718-724. (PMID: 32661059)
      Nat Commun. 2023 May 5;14(1):2610. (PMID: 37147288)
      PLoS One. 2022 Feb 3;17(2):e0263370. (PMID: 35113934)
      BMC Biol. 2022 Jan 10;20(1):13. (PMID: 35012549)
      RMD Open. 2023 Aug;9(3):. (PMID: 37562857)
    • Contributed Indexing:
      Keywords: COVID-19; Histone 3; Interferon; Neutrophils; PAD4; Proliferating cell nuclear antigen
    • Accession Number:
      0 (Proliferating Cell Nuclear Antigen)
      9008-11-1 (Interferons)
      0 (PCNA protein, human)
      0 (IFIT1 protein, human)
      0 (IFIT2 protein, human)
      0 (STAT1 Transcription Factor)
      0 (Adaptor Proteins, Signal Transducing)
      0 (STAT1 protein, human)
      0 (Chemokine CXCL10)
      0 (MX1 protein, human)
      0 (RNA-Binding Proteins)
      0 (Apoptosis Regulatory Proteins)
      0 (Myxovirus Resistance Proteins)
    • Publication Date:
      Date Created: 20250227 Date Completed: 20250227 Latest Revision: 20250302
    • Publication Date:
      20250302
    • Accession Number:
      PMC11867639
    • Accession Number:
      10.1159/000543633
    • Accession Number:
      40015257